0000000000223467

AUTHOR

Antonino Musarra

showing 3 related works from this author

Overcoming Barriers to the Effective Management of Severe Asthma in Italy.

2021

Pierluigi Paggiaro,1 Simona Barbaglia,2 Stefano Centanni,3,4 Davide Croce,5 Enrico Desideri,6 Saffi Giustini,7,8 Claudio Micheletto,9 Antonino Musarra,10 Nicola Scichilone,11 Ugo Trama,12 Maria Teresa Zedda,7,13 Giorgio Walter Canonica14 1Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy; 2Associazione Nazionale Pazienti “Respiriamo Insieme”, Padova, Italy; 3Department of Health Sciences, Università degli Studi di Milano, Milan, Italy; 4Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy; 5Center for Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, I…

Pulmonary and Respiratory Medicinesevere asthmaReferralunmet needsSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroids03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Biologic therapy Expert opinion Oral corticosteroids Severe asthma Unmet needsMultidisciplinary approachHealth careJournal of Asthma and AllergyImmunology and AllergyMedicine0601 history and archaeologybiologic therapyInformation exchange060102 archaeologybusiness.industryMedical record06 humanities and the artsRC581-607medicine.diseaseExpert OpinionIntegrated care030228 respiratory systemMedical emergencyImmunologic diseases. AllergybusinessPatient educationJournal of asthma and allergy
researchProduct

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

2020

Background: Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. Methods: We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months). Results: FEV1% improved significantly after MEP. Mean FEF25-75 also increased from 37.4 ± 25.4% to 47.2 ± 27.2% (p < 0.0001). Mean baseline blood eosinophil level was 712 ± 731/μ…

MaleOmalizumabFEF(25-75)step-down0302 clinical medicineMaintenance therapyAdrenal Cortex HormonesSettore MED/10Pharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicinesmall airwaysAsthma exacerbationsmepolizumabMiddle AgedAnesthesiaFEF25-75CorticosteroidDrug Therapy CombinationFemalemedicine.drugPulmonary and Respiratory Medicinesevere asthmamedicine.drug_classMepolizumab Severe asthma Real-life Small airways FEF25-75 Oral corticosteroids Step-down EffectiveneseffectivenessSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroidsAntibodies Monoclonal HumanizedNO03 medical and health sciencesEffectiveness FEF 25-75 Mepolizumab Oral corticosteroids Real-life Severe asthma Small airways Step-downmedicineHumansIn real lifeFEFreal-lifeAgedRetrospective StudiesBiologic markerbusiness.industryEffectivenesBiochemistry (medical)Effectiveness; FEF; 25-75; Mepolizumab; Oral corticosteroids; Real-life; Severe asthma; Small airways; Step-downAirway obstructionmedicine.diseaseAsthmaBlood Cell Countrespiratory tract diseasesAirway ObstructionEosinophils030228 respiratory systemeffectiveness; FEF(25-75); mepolizumab; oral corticosteroids; real-life; severe asthma; small airways; step-down25-75businessMepolizumab
researchProduct

Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity?

2014

Background: This study was designed to assess if illness perception, mood state and coping strategies differ according to allergic rhinitis (AR) persistence and severity. Methods: Illness perception, mood profiles, coping behaviors and rhinitis symptoms were assessed by means of validated tools inpatients classified according to the Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines. Results: Two hundred and thirty-one patients underwent data analysis. No difference in age, sex, socio-economic status, smoking habits was detected comparing patients according to AR severity, duration or 4 ARIA classes. Patients with intermittent AR reported higher scores than those with persistent A…

Persistence (psychology)Smoking habitbusiness.industryRhinitis Allergic SeasonalCoping behaviorGeneral MedicineAllergensSettore MED/10 - Malattie Dell'Apparato RespiratorioProfile of mood statesmedicine.diseaseRhinitis AllergicSeverity of Illness IndexAsthmadyspnea rhinitis mood stateIllness perceptionsMoodCross-Sectional StudiesOtorhinolaryngologymedicineMood stateHumansbusinessAsthmaClinical psychologyRhinitis
researchProduct